ABEVMY

This brand name is authorized in Croatia, Estonia, Ireland, Lithuania, New Zealand, Poland, South Africa, Tunisia.

Active ingredients

The drug ABEVMY contains one active pharmaceutical ingredient (API):

1	Bevacizumab UNII 2S9ZZM9Q9V - BEVACIZUMAB
	Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.
	Read more about Bevacizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FG01	Bevacizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1846841, 1846852, 1846863, 1846874, 1846885
LT	Valstybinė vaistų kontrolės tarnyba	1092483, 1092484, 1092485, 1092486, 1092487
NZ	Medicines and Medical Devices Safety Authority	21621
PL	Rejestru Produktów Leczniczych	100449085
TN	Direction de la Pharmacie et du Médicament	20343021H, 20343022H
ZA	Health Products Regulatory Authority	55/26/0256, 55/26/0257